Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.
Acyclovir is an effective agent for the treatment of herpes virus infections, however, the pharmacokinetics of the drug are altered in renal failure. We studied this drug in a continuous ambulatory peritoneal dialysis (CAPD) patient who was immunocompromised and had cutaneous herpes infection. The elimination half-life (17.1 hours) was similar to that reported for end-stage renal disease (ESRD) patients, while the volume of the central compartment (29.6 L/1.73 m2), the steady state volume of distribution (68.1 L/1.73 m2), and the total body clearance (48.3 mL/min/1.73 m2) were greater. The mean CAPD clearance was only 4.4 mL/min, with less than 10% of an administered dose being recovered in the 24-hour dialysate. Further studies are needed to establish a dosing regimen for CAPD patients.
D000212:Acyclovir / Q000008:administration & dosage / Q000378:metabolism*; D000368:Aged; D006207:Half-Life; D006561:Herpes Simplex / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D007700:Kinetics; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory
D000212:Acyclovir